Literature DB >> 12644887

Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.

Einat Even-Sapir1, Ora Israel.   

Abstract

Until recently, gallium-67 scintigraphy (GS) has been the best available functional imaging modality for evaluating patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). The diagnostic accuracy of GS in detecting lymphoma is based on optimisation of the imaging protocol, knowledge of potential physiological and benign sites of (67)Ga uptake, and the Ga avidity characteristics of the individual lymphoma. As (67)Ga is a tumour viability agent, the role of GS is primarily at follow-up. A residual mass persisting on CT after treatment poses a common clinical dilemma: it may indicate the presence of viable lymphoma, which requires further treatment, or it can be benign, consisting of only fibrotic and necrotic tissues. GS can successfully differentiate between these conditions. Routine follow-up with GS may allow early diagnosis of recurrence and early institution of treatment. Reversion of a positive GS to a negative test, and the rapidity with which this occurs has a high predictive value for the outcome of the individual patient. Lymphoma showing a normal GS early during treatment has a better prognosis than lymphoma with persistence of pathological findings. Other tumour-seeking single-photon emitting agents, such as thallium-201, technetium-99m methoxyisobutylisonitrile and indium-111 octreotide, have been investigated in lymphoma, primarily as an alternative to GS in specific clinical settings, but are of limited value. The role of radioimmunoscintigraphy is gaining importance in conjunction with radioimmunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) imaging of lymphoma using either dedicated or camera-based PET systems is gradually replacing GS for assessment of lymphoma. FDG overcomes some of the limitations of GS while sharing its tumour viability characteristics. The extensive clinical knowledge and experience accumulated over three decades with GS in lymphoma provides a solid background as well as a model for the assessment of new functional imaging techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644887     DOI: 10.1007/s00259-003-1164-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  160 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.

Authors:  P L Zinzani; M Zompatori; M Bendandi; G Battista; S Fanti; E Barbieri; F Gherlinzoni; M R Rimondi; G Frezza; P Pisi; E Merla; A Gozzetti; R Canini; N Monetti; L Babini; S Tura
Journal:  Leuk Lymphoma       Date:  1996-06

3.  Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes.

Authors:  D Piwnica-Worms; B L Holman
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

4.  New aspects of cellular thallium uptake: Tl+-Na+-2Cl(-)-cotransport is the central mechanism of ion uptake.

Authors:  M J Sessler; P Geck; F D Maul; G Hör; D L Munz
Journal:  Nuklearmedizin       Date:  1986-02       Impact factor: 1.379

5.  Thoracoscopy or CT-guided biopsy for residual intrathoracic masses after treatment of lymphoma.

Authors:  D Gossot; P Girard; E de Kerviler; P Brice; J D Rain; T Leblanc; D Grunenwald
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

6.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

7.  Transferrin receptors and gallium-67 uptake in vitro.

Authors:  D C Chen; B Newman; R M Turkall; M F Tsan
Journal:  Eur J Nucl Med       Date:  1982

8.  Lymphoma of the mediastinum and neck: evaluation with Ga-67 imaging and CT correlation.

Authors:  S R Drossman; R G Schiff; G D Kronfeld; J McNamara; J C Leonidas
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

9.  Gallium scanning in the management of mediastinal Hodgkin's disease.

Authors:  B R Wylie; A E Southee; D E Joshua; A F McLaughlin; J Gibson; B F Hutton; J G Morris; H Kronenberg
Journal:  Eur J Haematol       Date:  1989-04       Impact factor: 2.997

10.  The effects of inadvertent administration of antineoplastic agents prior to Ga-67 injection: concise communication.

Authors:  C Bekerman; D G Pavel; J Bitran; U Y Ryo; S Pinsky
Journal:  J Nucl Med       Date:  1984-04       Impact factor: 10.057

View more
  14 in total

Review 1.  Positron emission tomography in the management of lymphomas: a summary.

Authors:  M J O'Doherty; P J Hoskin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

2.  67Ga scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

Review 3.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma.

Authors:  Barbara Palumbo; Silvio Sivolella; Isabella Palumbo; Anna Marina Liberati; Renato Palumbo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-14       Impact factor: 9.236

Review 5.  Technological development and advances in single-photon emission computed tomography/computed tomography.

Authors:  Youngho Seo; Carina Mari; Bruce H Hasegawa
Journal:  Semin Nucl Med       Date:  2008-05       Impact factor: 4.446

Review 6.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

7.  (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.

Authors:  T Gmeiner Stopar; I Mlinaric-Rascan; J Fettich; S Hojker; S J Mather
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-20       Impact factor: 9.236

8.  Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.

Authors:  Jonathan W Engle; Hao Hong; Yin Zhang; Hector F Valdovinos; Duane V Myklejord; Todd E Barnhart; Charles P Theuer; Robert J Nickles; Weibo Cai
Journal:  Mol Pharm       Date:  2012-04-21       Impact factor: 4.939

Review 9.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

10.  18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma.

Authors:  M J Shelly; S McDermott; O J O'Connor; M A Blake
Journal:  ISRN Hematol       Date:  2012-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.